The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”
Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”
Declining reimbursement remains the number one concern of practicing urologists, according to findings from the 8th installment of Urology Times' exclusive State of the Specialty survey.
British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.
Ceftolozane/tazobactam, an investigational antibiotic, showed positive top-line results in a pivotal phase III clinical trial of the drug’s use in complicated urinary tract infections, Cubist Pharmaceuticals, Inc. reported.
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.
Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score than men who ate a typical Western diet, UCLA researchers reported.
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.
Older men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.
GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.
Contrary to popular belief and scientific predictions, a man’s patency after vasectomy reversal is possible almost 40 years after the original vasectomy, according to a study of more than 1,200 reversals that the authors say is the largest such study ever published.
Men with prostate cancer treated with androgen deprivation therapy had significant improvement in strength and exercise capacity following a 10-week program of physical activity, education, and support, according to a study reported at the AUA annual meeting in San Diego.
A new staging system for anterior urethral strictures is easy to use, demonstrates good reliability, and is expected to have useful applications in research and clinical care, say researchers from Cornell University’s Weill Medical College, New York.
Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Juan Reyna, MD, is the new president of the Large Urology Group Practice Association.
As the year comes to an end, federal lawmakers still have much to address with Obamacare’s problematic launch and time running out to pass a repeal of the fundamentally flawed Medicare sustainable growth rate by the end of the year.
Men with advanced prostate cancer had similar survival with intermittent or continuous androgen deprivation therapy, pooled data from two randomized trials showed.
The use of voided midstream urine cultures in diagnosing cystitis has limited value but can be modified to avoid undertreatment and inappropriate treatment, according to a recently published study.
Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.
An investigational minimally invasive device was found safe and effective in limiting rapid pressure changes within the bladder to reduce symptoms of stress urinary incontinence, the authors of a recently published trial reported.
No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.
"Training more urologists is a long-term plan that’s needed, but PAs/NPs aren’t a solution everywhere because the distribution of specialists can vary, even within the same state."
With such an overwhelming number of choices, it can be daunting to find apps that have practical use for urologists or their patients, and also work well. In this article, I provide some direction and references to help you find the right app for your purpose.
A relatively simple technique called the spousal lifetime access trust has proven especially advantageous and popular among those who have remarried and want to provide for children from a prior marriage.
If you’re in private practice, your profits will be directly affected by how your staff can manage and adapt to ACA-related coverage changes.
In the lawsuit, the physician was accused of not timely responding to the information that there was no urine returned after catheterization.
In this column, we outline the issues that we know will be important in 2014 and discuss what we think might be implemented by Medicare for 2014.
Urologists Alexander Kutikov, MD, and Todd M. Morgan, MD, discuss the impetus behind UrologyMatch.com and drawMD and how they benefit physicians and patients.